Format

Send to

Choose Destination
J Gen Physiol. 2018 Oct 23. pii: jgp.201812177. doi: 10.1085/jgp.201812177. [Epub ahead of print]

Chromomycin A2 potently inhibits glucose-stimulated insulin secretion from pancreatic β cells.

Author information

1
Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX michael.kalwat@utsouthwestern.edu.
2
Department of Pharmacy, Woosuk University, Wanju, South Korea.
3
Department of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, CA.
4
Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX.

Abstract

Modulators of insulin secretion could be used to treat diabetes and as tools to investigate β cell regulatory pathways in order to increase our understanding of pancreatic islet function. Toward this goal, we previously used an insulin-linked luciferase that is cosecreted with insulin in MIN6 β cells to perform a high-throughput screen of natural products for chronic effects on glucose-stimulated insulin secretion. In this study, using multiple phenotypic analyses, we found that one of the top natural product hits, chromomycin A2 (CMA2), potently inhibited insulin secretion by at least three potential mechanisms: disruption of Wnt signaling, interference of β cell gene expression, and partial suppression of Ca2+ influx. Chronic treatment with CMA2 largely ablated glucose-stimulated insulin secretion even after washout, but it did not inhibit glucose-stimulated generation of ATP or Ca2+ influx. However, by using the KATP channel opener diazoxide, we uncovered defects in depolarization-induced Ca2+ influx that may contribute to the suppressed secretory response. Glucose-responsive ERK1/2 and S6 phosphorylation were also disrupted by chronic CMA2 treatment. By querying the FUSION bioinformatic database, we revealed that the phenotypic effects of CMA2 cluster with a number of Wnt-GSK3 pathway-related genes. Furthermore, CMA2 consistently decreased GSK3β phosphorylation and suppressed activation of a β-catenin activity reporter. CMA2 and a related compound, mithramycin, are known to have DNA interaction properties, possibly abrogating transcription factor binding to critical β cell gene promoters. We observed that CMA2 but not mithramycin suppressed expression of PDX1 and UCN3. However, neither expression of INSI/II nor insulin content was affected by chronic CMA2. The mechanisms of CMA2-induced insulin secretion defects may involve components both proximal and distal to Ca2+ influx. Therefore, CMA2 is an example of a chemical that can simultaneously disrupt β cell function through both noncytotoxic and cytotoxic mechanisms. Future therapeutic applications of CMA2 and similar aureolic acid analogues should consider their potential effects on pancreatic islet function.

PMID:
30352794
DOI:
10.1085/jgp.201812177

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center